Screener
Amgen AMGN Business Segments — Sales and marketing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:SellingAndMarketingExpense.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Manufacturing cost of sales(1)(2) | 2,139 | 2,484 | 4,319 | 5,012 |
| Profit share and royalties in cost of sales(1) | 672 | 527 | 1,236 | 967 |
| Research and development(1) | 1,868 | 1,744 | 3,587 | 3,230 |
| Sales and marketing(1) | 1,155 | 1,137 | 2,289 | 2,203 |
| General and administrative(1) | 590 | 554 | 1,058 | 1,175 |
| Other segment items(3) | 314 | 557 | 227 | (5) |
| Interest income | (125) | (86) | (226) | (212) |
| Interest expense, net | 673 | 694 | 1,330 | 1,417 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's business segments — sales and marketing?
- Amgen (AMGN) reported business segments — sales and marketing of $1.16B in Q2 2026.
- How has Amgen's business segments — sales and marketing changed year-over-year?
- Amgen's business segments — sales and marketing increased by 1.6% year-over-year, from $1.14B to $1.16B.
- What does business segments — sales and marketing mean?
- Includes costs related to the promotion, advertising, and sales force activities required to commercialize the company's therapeutic portfolio. This expense is critical for maintaining market share against competitors and educating healthcare providers about product benefits. It directly impacts the company's ability to drive adoption of new and existing drugs.
Ask your AI about Amgen's business segments — sales and marketing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude